Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016’, provides in depth analysis on Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted pipeline therapeutics.

The report provides comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)
  • The report reviews Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Overview
Therapeutics Development
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Stage of Development
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Therapy Area
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Indication
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Companies
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Companies Involved in Therapeutics Development
Actelion Ltd
Arena Pharmaceuticals, Inc.
AstraZeneca Plc
Celgene Corporation
GlaxoSmithKline Plc
Meiji Seika Pharma Co., Ltd.
Novartis AG
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Drug Profiles
AKP-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cenerimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-9531 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIBR-0213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ozanimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1PR1 for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Dormant Projects
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Discontinued Products
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Featured News & Press Releases
May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis
Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS
Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases
Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis
Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases
Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week
Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod
Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases
Jul 29, 2015: Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases
Jul 09, 2015: Suzhou Connect Biopharma Announces Patent Issuance Covering CBP-307 - a Clinical-stage Second Generation S1P1 Immune Modulator
Jul 01, 2015: Akaal Pharma, Australia extends collaboration with GVK BIO for formulations development services to support Phase 2 Clinical studies for Topical Treatment of Psoriasis
Jun 25, 2015: New Data Supporting Gradual Up-Titration Of Ponesimod To Mitigate First-Dose Cardiodynamic Effects To Be Presented At Eacpt 2015
Jun 16, 2015: Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Actelion Ltd, H1 2016
Pipeline by Arena Pharmaceuticals, Inc., H1 2016
Pipeline by AstraZeneca Plc, H1 2016
Pipeline by Celgene Corporation, H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016
Pipeline by Novartis AG, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook